How to buy Novus Therapeutics stock | $20.03

Novus Therapeutics, Inc is a biotechnology business based in the US. Novus Therapeutics shares (NVUS) are listed on the NASDAQ and all prices are listed in US Dollars. Novus Therapeutics employs 7 staff and has a market cap (total outstanding shares value) of USD$28.8 million.

How to buy shares in Novus Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Novus Therapeutics. Find the stock by name or ticker symbol: NVUS. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Novus Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$20.03, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Novus Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Novus Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Novus Therapeutics share price

Use our graph to track the performance of NVUS stocks over time.

Novus Therapeutics shares at a glance

• Key figures

Information last updated 2020-12-09.

Latest market close	USD$20.03
52-week range	USD$4.5 - USD$26.44
50-day moving average	USD$20.8521
200-day moving average	USD$13.6127
Wall St. target price	USD$23.37
PE ratio	2.0936
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-1.702

Buy Novus Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Novus Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Novus Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Novus Therapeutics price performance over time

Historical closes compared with the close of $20.03 from 2020-12-09

1 week (2021-01-08)	37.19%
1 month (2020-12-16)	9.16%
3 months (2020-10-15)	20.66%
6 months (2020-07-15)	4,082.50%

1 year (2020-01-15)	2,691.64%
2 years (2019-01-15)	765.23%
3 years (2018-01-12)	438.89%
5 years (2016-01-15)	275.80%

Is Novus Therapeutics under- or over-valued?

Valuing Novus Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novus Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Novus Therapeutics's P/E ratio

Novus Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 2x. In other words, Novus Therapeutics shares trade at around 2x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Novus Therapeutics's PEG ratio

Novus Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.01. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novus Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Novus Therapeutics financials

Gross profit TTM	USD$0
Return on assets TTM	-7.29%
Return on equity TTM	-21.07%
Profit margin	0%
Book value	$16.872
Market capitalisation	USD$28.8 million

TTM: trailing 12 months

Shorting Novus Therapeutics shares

There are currently 115,315 Novus Therapeutics shares held short by investors – that's known as Novus Therapeutics's "short interest". This figure is 299.1% up from 28,893 last month.

There are a few different ways that this level of interest in shorting Novus Therapeutics shares can be evaluated.

Novus Therapeutics's "short interest ratio" (SIR)

Novus Therapeutics's "short interest ratio" (SIR) is the quantity of Novus Therapeutics shares currently shorted divided by the average quantity of Novus Therapeutics shares traded daily (recently around 34733.43373494). Novus Therapeutics's SIR currently stands at 3.32. In other words for every 100,000 Novus Therapeutics shares traded daily on the market, roughly 3320 shares are currently held short.

However Novus Therapeutics's short interest can also be evaluated against the total number of Novus Therapeutics shares, or, against the total number of tradable Novus Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novus Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Novus Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1089% of the tradable shares (for every 100,000 tradable Novus Therapeutics shares, roughly 109 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novus Therapeutics.

Find out more about how you can short Novus Therapeutics stock.

Novus Therapeutics share dividends

We're not expecting Novus Therapeutics to pay a dividend over the next 12 months.

Have Novus Therapeutics's shares ever split?

Novus Therapeutics's shares were split on a 1:18 basis on 5 October 2020. So if you had owned 18 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Novus Therapeutics shares – just the quantity. However, indirectly, the new 1700% higher share price could have impacted the market appetite for Novus Therapeutics shares which in turn could have impacted Novus Therapeutics's share price.

Novus Therapeutics share price volatility

Over the last 12 months, Novus Therapeutics's shares have ranged in value from as little as $4.5 up to $26.44. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Novus Therapeutics's is 2.3075. This would suggest that Novus Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Novus Therapeutics overview

Novus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.

Frequently asked questions

• What percentage of Novus Therapeutics is owned by insiders or institutions?

  Currently 1.84% of Novus Therapeutics shares are held by insiders and 49.135% by institutions.

• How many people work for Novus Therapeutics?

  Latest data suggests 7 work at Novus Therapeutics.

• When does the fiscal year end for Novus Therapeutics?

  Novus Therapeutics's fiscal year ends in December.

• Where is Novus Therapeutics based?

  Novus Therapeutics's address is: 19900 MacArthur Boulevard, Irvine, CA, United States, 92612

• What is Novus Therapeutics's ISIN number?

  Novus Therapeutics's international securities identification number is: US67011N2045

• What is Novus Therapeutics's CUSIP number?

  Novus Therapeutics's Committee on Uniform Securities Identification Procedures number is: 67011N105